Belimumab for systemic lupus erythematosus
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Belimumab for Systemic Lupus Erythematosus." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305394/all/Belimumab_for_systemic_lupus_erythematosus.
Belimumab for systemic lupus erythematosus. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305394/all/Belimumab_for_systemic_lupus_erythematosus. Accessed October 3, 2024.
Belimumab for systemic lupus erythematosus. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305394/all/Belimumab_for_systemic_lupus_erythematosus
Belimumab for Systemic Lupus Erythematosus [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2024 October 03]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305394/all/Belimumab_for_systemic_lupus_erythematosus.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Belimumab for systemic lupus erythematosus
ID - 1305394
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305394/all/Belimumab_for_systemic_lupus_erythematosus
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -